Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EPS (Weighted Average and Diluted) (2022 - 2025)

Abeona Therapeutics has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at -$0.34 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.34 for Q4 2025, down 142.86% from a year ago — trailing twelve months through Dec 2025 was $1.03 (up 147.03% YoY), and the annual figure for FY2025 was $1.01, up 165.16%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.34 at Abeona Therapeutics, down from -$0.1 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ABEO hit a ceiling of $1.71 in Q2 2025 and a floor of -$1.16 in Q1 2024.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.34 (2025), compared with a mean of -$0.19.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 223.08% in 2023 and later soared 757.69% in 2025.
  • Abeona Therapeutics' EPS (Weighted Average and Diluted) stood at $0.52 in 2022, then tumbled by 223.08% to -$0.64 in 2023, then soared by 78.12% to -$0.14 in 2024, then tumbled by 142.86% to -$0.34 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.34 (Q4 2025), -$0.1 (Q3 2025), and $1.71 (Q2 2025) per Business Quant data.